BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 35932329)

  • 21. Prognostic Value of 2-Deoxy-2-[
    Dai N; Zhou Y; Deng S; Sang S; Wu Y
    Contrast Media Mol Imaging; 2021; 2021():5510825. PubMed ID: 33958977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can physiologic colonic [
    Sachpekidis C; Stein-Thoeringer CK; Kopp-Schneider A; Weru V; Dimitrakopoulou-Strauss A; Hassel JC
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3709-3722. PubMed ID: 37452874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
    Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
    J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.
    Dai N; Liu H; Deng S; Sang S; Wu Y
    Technol Cancer Res Treat; 2021; 20():15330338211056478. PubMed ID: 34806464
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of 2-[
    Schweighofer-Zwink G; Manafi-Farid R; Kölblinger P; Hehenwarter L; Harsini S; Pirich C; Beheshti M
    Eur J Radiol; 2022 Jan; 146():110107. PubMed ID: 34922117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of baseline
    Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
    Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic evaluation of the prognostic value of
    Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
    Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis.
    Chen L; Wu X; Ma X; Guo L; Zhu C; Li Q
    Medicine (Baltimore); 2017 Feb; 96(6):e5913. PubMed ID: 28178131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
    Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple metabolic parameters and visual assessment of
    Ren Y; Liu J; Wang L; Luo Y; Ding X; Shi A; Liu J
    Abdom Radiol (NY); 2020 Nov; 45(11):3569-3580. PubMed ID: 32274551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing immune organs on
    Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of metabolic parameters measured by
    Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
    J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of
    Albano D; Camoni L; Giubbini R; Bertagna F
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e897-e904. PubMed ID: 32703751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas.
    Prieto Prieto JC; Vallejo Casas JA; Hatzimichael E; Fotopoulos A; Kiortsis DN; Sioka C
    Ann Nucl Med; 2020 Oct; 34(10):707-717. PubMed ID: 32924071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
    Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
    Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
    Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.